A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

NCT00741234 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Hematologic Malignancies
Myelodysplastic Syndrome

Interventions

DRUG: SB939
DRUG: Azacitidine

Sponsor

S*BIO